Plus Therapeutics Inc Stock Price, News & Analysis

Plus Therapeutics (PSTV) announced that Dr. Andrew Brenner will host a live webinar on October 9, 2022, focusing on a new targeted radiation therapy for leptomeningeal metastases related to breast and lung cancers. This session is part of the Musella Foundation Webinar Series. Leptomeningeal metastases pose significant treatment challenges, and the webinar aims to educate patients about potential therapies. Plus Therapeutics is a clinical-stage pharmaceutical company developing innovative treatments for cancer, leveraging advanced delivery technologies.

Plus Therapeutics (PSTV) announced that its data on Leptomeningeal metastases has been recognized as a “Top Rated Oral Presentation” by EANM. The company will present findings from ongoing clinical trials on its investigational drug, Rhenium-186 NanoLiposome (¹⁸⁶RNL), for treating recurrent glioblastoma and leptomeningeal metastases at the 35th Annual Congress of EANM in Barcelona from October 15-19, 2022. The presentations will detail safety and feasibility trials for ¹⁸⁶RNL, highlighting its potential in challenging cancer treatments.

Plus Therapeutics (PSTV) has secured a $17.6 million grant from CPRIT to fund the development of its lead investigational treatment, Rhenium-186 NanoLiposome, for leptomeningeal metastases. This funding, expected to be received by October 31, 2022, allows for $3.7 million in Year 1, $6.7 million in Year 2, and $7.2 million in Year 3, extending the company's cash runway through 2025. As of June 30, 2022, Plus Therapeutics reported $18.1 million in cash, bolstering its financial position for ongoing clinical trials and operational activities.

Plus Therapeutics announced Phase 1 results for ¹⁸⁶RNL, showing significant safety and survival benefits in patients with recurrent glioblastoma. The trial, presented at ESMO 2022, demonstrated a median overall survival of 22.9 months for patients receiving over 100 Gray of radiation, compared to 5.6 months for lower doses. The company will advance to Phase 2, funded by the NIH, to explore expanded dosing and larger tumors. Observations include no dose-limiting toxicities and enhanced radiation delivery potential, marking a promising step towards treatment advancement.

Plus Therapeutics, Inc. (Nasdaq: PSTV) announced that CEO Marc Hedrick will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 2:00 p.m. ET, in New York City. The presentation will focus on the company’s development of targeted radiotherapeutics for rare cancers. Investors interested in meetings with management should contact the conference coordinator. An archived replay of the presentation will be available on the Plus Therapeutics website for 90 days post-event.

Plus Therapeutics (PSTV) announced the initiation of the ReSPECT-GBM Phase 2 trial, focusing on the Rhenium-186 NanoLiposome (¹⁸⁶RNL) for treating recurrent glioblastoma (GBM). The FDA has approved the trial, emphasizing dose exploration and the collection of safety and efficacy data. A future registrational trial will prioritize overall survival as the main endpoint. The trial's principal investigator will provide updates at the ESMO Congress. Plus Therapeutics continues to develop innovative targeted radiotherapeutics for challenging cancers, backed by NIH and CPRIT funding.

Plus Therapeutics, Inc. (PSTV) has announced a significant update following a Type C meeting with the FDA regarding the cGMP production of its investigational radiotherapeutic, ¹⁸⁶RNL, aimed at treating recurrent glioblastoma. The FDA supports the company’s CMC practices, aligning with its proposed manufacturing and release strategies. This endorsement is crucial as Plus Therapeutics prepares for ongoing and future ReSPECT™ clinical trials, with cGMP ¹⁸⁶RNL expected to be available in the second half of 2022. The company emphasizes that this regulatory clarity mitigates risks of potential delays.

Plus Therapeutics, Inc. (PSTV) has announced an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022 regarding its Phase 1/2a ReSPECT-GBM™ clinical trial. The trial evaluates Rhenium-186 NanoLiposome (186RNL) for treating recurrent glioblastoma. The presentation is scheduled for September 9, 2022, at 14:00 CEST, led by Dr. Andrew J. Brenner. This investigation aims to demonstrate the safety and efficacy of 186RNL in delivering high doses of radiation directly to tumors through Convection Enhanced Delivery (CED).

Plus Therapeutics (PSTV) has secured a $17.6 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance Rhenium-186 NanoLiposome (186RNL) aimed at treating leptomeningeal metastases. This funding will cover a significant portion of the developmental costs for the next three years. Additionally, the clinical trial for 186RNL continues to progress with Cohort 1 enrollment completed, demonstrating no dose-limiting toxicities. The therapy has received FDA Fast Track designation, indicating significant potential in addressing this severe cancer complication.